Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 75 entries
Sorted by: Best Match Show Resources per page
Nodular Cutaneous Amyloidosis Resembling a Giant Tumor.

Case reports in dermatology

Haverkampf S, Evert K, Schröder J, Schreml S.
PMID: 27293389
Case Rep Dermatol. 2016 Feb 03;8(1):22-5. doi: 10.1159/000443950. eCollection 2016.

A 79-year-old man presented with a large tumor on the left side of his head, which had grown over 5 years. Regional lymph nodes were impalpable and computed tomography revealed no signs of bone infiltration. Histology showed that the...

Cite
Haverkampf S, Evert K, Schröder J, et al. Nodular Cutaneous Amyloidosis Resembling a Giant Tumor. Case Rep Dermatol. 2016;8(1):22-5doi: 10.1159/000443950.
Haverkampf, S., Evert, K., Schröder, J., & Schreml, S. (2016). Nodular Cutaneous Amyloidosis Resembling a Giant Tumor. Case reports in dermatology, 8(1), 22-5. https://doi.org/10.1159/000443950
Haverkampf, Sonja, et al. "Nodular Cutaneous Amyloidosis Resembling a Giant Tumor." Case reports in dermatology vol. 8,1 (2016): 22-5. doi: https://doi.org/10.1159/000443950
Haverkampf S, Evert K, Schröder J, Schreml S. Nodular Cutaneous Amyloidosis Resembling a Giant Tumor. Case Rep Dermatol. 2016 Feb 03;8(1):22-5. doi: 10.1159/000443950. eCollection 2016. PMID: 27293389; PMCID: PMC4899645.
Copy Download .nbib Format: NLM
Amyloid and the cardiovascular system: A review of pathogenesis and pathology with clinical correlations.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology

Walley VM, Kisilevsky R, Young ID.
PMID: 25850907
Cardiovasc Pathol. 1995 Apr-Jun;4(2):79-102. doi: 10.1016/1054-8807(95)90411-l.

The process of amyloidogenesis may complicate diverse disease states. It may be systemic and have serious clinical sequelae; in other circumstances, it is a localized phenomenon and functionally insignificant. In many cases its manifestations may be predictable, with knowledge...

Cite
Walley VM, Kisilevsky R, Young ID. Amyloid and the cardiovascular system: A review of pathogenesis and pathology with clinical correlations. Cardiovasc Pathol. 1995;4(2):79-102doi: 10.1016/1054-8807(95)90411-l.
Walley, V. M., Kisilevsky, R., & Young, I. D. (1995). Amyloid and the cardiovascular system: A review of pathogenesis and pathology with clinical correlations. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology, 4(2), 79-102. https://doi.org/10.1016/1054-8807(95)90411-l
Walley, V M, et al. "Amyloid and the cardiovascular system: A review of pathogenesis and pathology with clinical correlations." Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology vol. 4,2 (1995): 79-102. doi: https://doi.org/10.1016/1054-8807(95)90411-l
Walley VM, Kisilevsky R, Young ID. Amyloid and the cardiovascular system: A review of pathogenesis and pathology with clinical correlations. Cardiovasc Pathol. 1995 Apr-Jun;4(2):79-102. doi: 10.1016/1054-8807(95)90411-l. PMID: 25850907.
Copy Download .nbib Format: NLM
Serum Free Light Chains in Neoplastic Monoclonal Gammopathies: Relative Under-Detection of Lambda Dominant Kappa/Lambda Ratio, and Underproduction of Free Lambda Light Chains, as Compared to Kappa Light Chains, in Patients With Neoplastic Monoclonal Gammopathies.

Journal of clinical medicine research

Lee WS, Singh G.
PMID: 29904440
J Clin Med Res. 2018 Jul;10(7):562-569. doi: 10.14740/jocmr3383w. Epub 2018 Jun 04.

BACKGROUND: Quantitative evaluation of serum free light chains is recommended for the work up of monoclonal gammopathies. Immunoglobulin light chains are generally produced in excess of heavy chains. In patients with monoclonal gammopathy, κ/λ ratio is abnormal less frequently...

Cite
Lee WS, Singh G. Serum Free Light Chains in Neoplastic Monoclonal Gammopathies: Relative Under-Detection of Lambda Dominant Kappa/Lambda Ratio, and Underproduction of Free Lambda Light Chains, as Compared to Kappa Light Chains, in Patients With Neoplastic Monoclonal Gammopathies. J Clin Med Res. 2018;10(7):562-569doi: 10.14740/jocmr3383w.
Lee, W. S., & Singh, G. (2018). Serum Free Light Chains in Neoplastic Monoclonal Gammopathies: Relative Under-Detection of Lambda Dominant Kappa/Lambda Ratio, and Underproduction of Free Lambda Light Chains, as Compared to Kappa Light Chains, in Patients With Neoplastic Monoclonal Gammopathies. Journal of clinical medicine research, 10(7), 562-569. https://doi.org/10.14740/jocmr3383w
Lee, Won Sok, and Singh, Gurmukh. "Serum Free Light Chains in Neoplastic Monoclonal Gammopathies: Relative Under-Detection of Lambda Dominant Kappa/Lambda Ratio, and Underproduction of Free Lambda Light Chains, as Compared to Kappa Light Chains, in Patients With Neoplastic Monoclonal Gammopathies." Journal of clinical medicine research vol. 10,7 (2018): 562-569. doi: https://doi.org/10.14740/jocmr3383w
Lee WS, Singh G. Serum Free Light Chains in Neoplastic Monoclonal Gammopathies: Relative Under-Detection of Lambda Dominant Kappa/Lambda Ratio, and Underproduction of Free Lambda Light Chains, as Compared to Kappa Light Chains, in Patients With Neoplastic Monoclonal Gammopathies. J Clin Med Res. 2018 Jul;10(7):562-569. doi: 10.14740/jocmr3383w. Epub 2018 Jun 04. PMID: 29904440; PMCID: PMC5997416.
Copy Download .nbib Format: NLM
Methods to study the structure of misfolded protein states in systemic amyloidosis.

Biochemical Society transactions

Fändrich M, Schmidt M.
PMID: 33929491
Biochem Soc Trans. 2021 Apr 30;49(2):977-985. doi: 10.1042/BST20201022.

Systemic amyloidosis is defined as a protein misfolding disease in which the amyloid is not necessarily deposited within the same organ that produces the fibril precursor protein. There are different types of systemic amyloidosis, depending on the protein constructing...

Cite
Fändrich M, Schmidt M. Methods to study the structure of misfolded protein states in systemic amyloidosis. Biochem Soc Trans. 2021;49(2):977-985doi: 10.1042/BST20201022.
Fändrich, M., & Schmidt, M. (2021). Methods to study the structure of misfolded protein states in systemic amyloidosis. Biochemical Society transactions, 49(2), 977-985. https://doi.org/10.1042/BST20201022
Fändrich, Marcus, and Schmidt, Matthias. "Methods to study the structure of misfolded protein states in systemic amyloidosis." Biochemical Society transactions vol. 49,2 (2021): 977-985. doi: https://doi.org/10.1042/BST20201022
Fändrich M, Schmidt M. Methods to study the structure of misfolded protein states in systemic amyloidosis. Biochem Soc Trans. 2021 Apr 30;49(2):977-985. doi: 10.1042/BST20201022. PMID: 33929491.
Copy Download .nbib Format: NLM
Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis.

Blood

Edwards CV, Rao N, Bhutani D, Mapara M, Radhakrishnan J, Shames S, Maurer MS, Leng S, Solomon A, Lentzsch S, Eisenberger A.
PMID: 34521113
Blood. 2021 Dec 23;138(25):2632-2641. doi: 10.1182/blood.2020009039.

Systemic immunoglobulin light-chain amyloidosis is characterized by pathologic deposition of immunoglobulin light chains as amyloid fibrils in vital organs, leading to organ impairment and eventual death. That the process is reversible was evidenced in an in vivo experimental model...

Cite
Edwards CV, Rao N, Bhutani D, et al. Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood. 2021;138(25):2632-2641doi: 10.1182/blood.2020009039.
Edwards, C. V., Rao, N., Bhutani, D., Mapara, M., Radhakrishnan, J., Shames, S., Maurer, M. S., Leng, S., Solomon, A., Lentzsch, S., & Eisenberger, A. (2021). Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood, 138(25), 2632-2641. https://doi.org/10.1182/blood.2020009039
Edwards, Camille Vanessa, et al. "Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis." Blood vol. 138,25 (2021): 2632-2641. doi: https://doi.org/10.1182/blood.2020009039
Edwards CV, Rao N, Bhutani D, Mapara M, Radhakrishnan J, Shames S, Maurer MS, Leng S, Solomon A, Lentzsch S, Eisenberger A. Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood. 2021 Dec 23;138(25):2632-2641. doi: 10.1182/blood.2020009039. PMID: 34521113.
Copy Download .nbib Format: NLM
Urinary biopyrrins and free immunoglobin light chains are biomarker candidates for screening at-risk mental state in adolescents.

Early intervention in psychiatry

Wake R, Araki T, Fukushima M, Matsuda H, Inagaki T, Hayashida M, Hashioka S, Horiguchi J, Inagaki M, Miyaoka T, Oh-Nishi A.
PMID: 33966347
Early Interv Psychiatry. 2021 May 09; doi: 10.1111/eip.13154. Epub 2021 May 09.

BACKGROUND: Early diagnosis of individuals' at-risk mental state (ARMS) is important for preventing their pathogenesis or, at least, delaying onset of overt psychosis. Traditional diagnosis of ARMS subjects is mainly based on structured interviews, but future diagnosis would be...

Cite
Wake R, Araki T, Fukushima M, et al. Urinary biopyrrins and free immunoglobin light chains are biomarker candidates for screening at-risk mental state in adolescents. Early Interv Psychiatry. 2021;doi: 10.1111/eip.13154.
Wake, R., Araki, T., Fukushima, M., Matsuda, H., Inagaki, T., Hayashida, M., Hashioka, S., Horiguchi, J., Inagaki, M., Miyaoka, T., & Oh-Nishi, A. (2021). Urinary biopyrrins and free immunoglobin light chains are biomarker candidates for screening at-risk mental state in adolescents. Early intervention in psychiatry, . https://doi.org/10.1111/eip.13154
Wake, Rei, et al. "Urinary biopyrrins and free immunoglobin light chains are biomarker candidates for screening at-risk mental state in adolescents." Early intervention in psychiatry vol. (2021). doi: https://doi.org/10.1111/eip.13154
Wake R, Araki T, Fukushima M, Matsuda H, Inagaki T, Hayashida M, Hashioka S, Horiguchi J, Inagaki M, Miyaoka T, Oh-Nishi A. Urinary biopyrrins and free immunoglobin light chains are biomarker candidates for screening at-risk mental state in adolescents. Early Interv Psychiatry. 2021 May 09; doi: 10.1111/eip.13154. Epub 2021 May 09. PMID: 33966347.
Copy Download .nbib Format: NLM
Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis.

Blood

Edwards CV, Rao N, Bhutani D, Mapara M, Radhakrishnan J, Shames S, Maurer MS, Leng S, Solomon A, Lentzsch S, Eisenberger A.
PMID: 34521113
Blood. 2021 Dec 23;138(25):2632-2641. doi: 10.1182/blood.2020009039.

Systemic immunoglobulin light-chain amyloidosis is characterized by pathologic deposition of immunoglobulin light chains as amyloid fibrils in vital organs, leading to organ impairment and eventual death. That the process is reversible was evidenced in an in vivo experimental model...

Cite
Edwards CV, Rao N, Bhutani D, et al. Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood. 2021;138(25):2632-2641doi: 10.1182/blood.2020009039.
Edwards, C. V., Rao, N., Bhutani, D., Mapara, M., Radhakrishnan, J., Shames, S., Maurer, M. S., Leng, S., Solomon, A., Lentzsch, S., & Eisenberger, A. (2021). Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood, 138(25), 2632-2641. https://doi.org/10.1182/blood.2020009039
Edwards, Camille Vanessa, et al. "Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis." Blood vol. 138,25 (2021): 2632-2641. doi: https://doi.org/10.1182/blood.2020009039
Edwards CV, Rao N, Bhutani D, Mapara M, Radhakrishnan J, Shames S, Maurer MS, Leng S, Solomon A, Lentzsch S, Eisenberger A. Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood. 2021 Dec 23;138(25):2632-2641. doi: 10.1182/blood.2020009039. PMID: 34521113.
Copy Download .nbib Format: NLM
Diagnosing cardiac amyloidosis in every-day practice: A practical guide for the cardiologist.

International journal of cardiology. Heart & vasculature

Papathanasiou M, Carpinteiro A, Rischpler C, Hagenacker T, Rassaf T, Luedike P.
PMID: 32373710
Int J Cardiol Heart Vasc. 2020 Apr 27;28:100519. doi: 10.1016/j.ijcha.2020.100519. eCollection 2020 Jun.

Cardiac amyloidosis (CA) has emerged as a previously underestimated cause of heart failure and mortality. Underdiagnosis resulted mainly from unawareness of the true disease prevalence and the non-specific symptoms of the disease. CA results from extracellular deposition of misfolded...

Cite
Papathanasiou M, Carpinteiro A, Rischpler C, et al. Diagnosing cardiac amyloidosis in every-day practice: A practical guide for the cardiologist. Int J Cardiol Heart Vasc. 2020;28:100519doi: 10.1016/j.ijcha.2020.100519.
Papathanasiou, M., Carpinteiro, A., Rischpler, C., Hagenacker, T., Rassaf, T., & Luedike, P. (2020). Diagnosing cardiac amyloidosis in every-day practice: A practical guide for the cardiologist. International journal of cardiology. Heart & vasculature, 28100519. https://doi.org/10.1016/j.ijcha.2020.100519
Papathanasiou, Maria, et al. "Diagnosing cardiac amyloidosis in every-day practice: A practical guide for the cardiologist." International journal of cardiology. Heart & vasculature vol. 28 (2020): 100519. doi: https://doi.org/10.1016/j.ijcha.2020.100519
Papathanasiou M, Carpinteiro A, Rischpler C, Hagenacker T, Rassaf T, Luedike P. Diagnosing cardiac amyloidosis in every-day practice: A practical guide for the cardiologist. Int J Cardiol Heart Vasc. 2020 Apr 27;28:100519. doi: 10.1016/j.ijcha.2020.100519. eCollection 2020 Jun. PMID: 32373710; PMCID: PMC7191222.
Copy Download .nbib Format: NLM
Successful Pregnancy and Persistent Polyclonal B Cell Lymphocytosis (PPBL): A Case Study of a Rare Co-Existence.

The American journal of case reports

Dryllis G, Giannikos T, Konstantinou EA, Moustakas I, Christopoulos P, Pittaras T, Politou M, Valsami S.
PMID: 34936642
Am J Case Rep. 2021 Dec 22;22:e933746. doi: 10.12659/AJCR.933746.

BACKGROUND Persistent polyclonal B cell lymphocytosis (PPBL) is a benign clinical condition, which is characterized by persistent absolute polyclonal B lymphocytosis (>4.0 K/μL), with the presence of circulating binucleated lymphocytes on the peripheral blood smear and an extra 3...

Cite
Dryllis G, Giannikos T, Konstantinou EA, et al. Successful Pregnancy and Persistent Polyclonal B Cell Lymphocytosis (PPBL): A Case Study of a Rare Co-Existence. Am J Case Rep. 2021;22:e933746doi: 10.12659/AJCR.933746.
Dryllis, G., Giannikos, T., Konstantinou, E. A., Moustakas, I., Christopoulos, P., Pittaras, T., Politou, M., & Valsami, S. (2021). Successful Pregnancy and Persistent Polyclonal B Cell Lymphocytosis (PPBL): A Case Study of a Rare Co-Existence. The American journal of case reports, 22e933746. https://doi.org/10.12659/AJCR.933746
Dryllis, Georgios, et al. "Successful Pregnancy and Persistent Polyclonal B Cell Lymphocytosis (PPBL): A Case Study of a Rare Co-Existence." The American journal of case reports vol. 22 (2021): e933746. doi: https://doi.org/10.12659/AJCR.933746
Dryllis G, Giannikos T, Konstantinou EA, Moustakas I, Christopoulos P, Pittaras T, Politou M, Valsami S. Successful Pregnancy and Persistent Polyclonal B Cell Lymphocytosis (PPBL): A Case Study of a Rare Co-Existence. Am J Case Rep. 2021 Dec 22;22:e933746. doi: 10.12659/AJCR.933746. PMID: 34936642.
Copy Download .nbib Format: NLM
AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management.

JACC. CardioOncology

Witteles RM, Liedtke M.
PMID: 34396169
JACC CardioOncol. 2019 Sep 24;1(1):117-130. doi: 10.1016/j.jaccao.2019.08.002. eCollection 2019 Sep.

AL amyloidosis results from clonal production of immunoglobulin light chains, most commonly arising from a clonal plasma cell disorder. Once considered a nearly uniformly fatal disease, prognosis has improved markedly over the past 15 years, predominantly because of advances...

Cite
Witteles RM, Liedtke M. AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management. JACC CardioOncol. 2019;1(1):117-130doi: 10.1016/j.jaccao.2019.08.002.
Witteles, R. M., & Liedtke, M. (2019). AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management. JACC. CardioOncology, 1(1), 117-130. https://doi.org/10.1016/j.jaccao.2019.08.002
Witteles, Ronald M, and Liedtke, Michaela. "AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management." JACC. CardioOncology vol. 1,1 (2019): 117-130. doi: https://doi.org/10.1016/j.jaccao.2019.08.002
Witteles RM, Liedtke M. AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management. JACC CardioOncol. 2019 Sep 24;1(1):117-130. doi: 10.1016/j.jaccao.2019.08.002. eCollection 2019 Sep. PMID: 34396169; PMCID: PMC8352106.
Copy Download .nbib Format: NLM
AL amyloidosis: untangling new therapies.

Hematology. American Society of Hematology. Education Program

Bal S, Landau H.
PMID: 34889374
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):682-688. doi: 10.1182/hematology.2021000305.

Systemic light chain (AL) amyloidosis is a protein misfolding disorder characterized by the deposition of abnormal immunoglobulin light chains in fibrillary aggregates, resulting in end-organ damage. Several unique challenges face treating physicians, including delayed diagnosis, advanced vital organ involvement,...

Cite
Bal S, Landau H. AL amyloidosis: untangling new therapies. Hematology Am Soc Hematol Educ Program. 2021;2021(1):682-688doi: 10.1182/hematology.2021000305.
Bal, S., & Landau, H. (2021). AL amyloidosis: untangling new therapies. Hematology. American Society of Hematology. Education Program, 2021(1), 682-688. https://doi.org/10.1182/hematology.2021000305
Bal, Susan, and Landau, Heather. "AL amyloidosis: untangling new therapies." Hematology. American Society of Hematology. Education Program vol. 2021,1 (2021): 682-688. doi: https://doi.org/10.1182/hematology.2021000305
Bal S, Landau H. AL amyloidosis: untangling new therapies. Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):682-688. doi: 10.1182/hematology.2021000305. PMID: 34889374.
Copy Download .nbib Format: NLM
The Proximal Tubule Toxicity of Immunoglobulin Light Chains.

Kidney international reports

Sirac C, Batuman V, Sanders PW.
PMID: 34013100
Kidney Int Rep. 2021 Mar 03;6(5):1225-1231. doi: 10.1016/j.ekir.2021.02.026. eCollection 2021 May.

Plasma and B cells dyscrasias that overproduce monoclonal immunoglobulin free light chains (FLCs) affect the kidney frequently in various ways. The hematologic dyscrasia responsible for the production of FLCs may or may not meet the criteria for cancer, such...

Cite
Sirac C, Batuman V, Sanders PW. The Proximal Tubule Toxicity of Immunoglobulin Light Chains. Kidney Int Rep. 2021;6(5):1225-1231doi: 10.1016/j.ekir.2021.02.026.
Sirac, C., Batuman, V., & Sanders, P. W. (2021). The Proximal Tubule Toxicity of Immunoglobulin Light Chains. Kidney international reports, 6(5), 1225-1231. https://doi.org/10.1016/j.ekir.2021.02.026
Sirac, Christophe, et al. "The Proximal Tubule Toxicity of Immunoglobulin Light Chains." Kidney international reports vol. 6,5 (2021): 1225-1231. doi: https://doi.org/10.1016/j.ekir.2021.02.026
Sirac C, Batuman V, Sanders PW. The Proximal Tubule Toxicity of Immunoglobulin Light Chains. Kidney Int Rep. 2021 Mar 03;6(5):1225-1231. doi: 10.1016/j.ekir.2021.02.026. eCollection 2021 May. PMID: 34013100; PMCID: PMC8116766.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 75 entries